Tradewinds Capital Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Tradewinds Capital Management’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-30	Closed	-$2K	–	785
2021 Q4	$2K	Hold	30	–	–	﹤0.01%	659
2021 Q3	$3K	Hold	30	–	–	﹤0.01%	610
2021 Q2	$3K	Buy	+30	New	+$2.62K	﹤0.01%	618
2018 Q4	–	Sell	-50	Closed	-$3K	–	626
2018 Q3	$3K	Buy	+50	New	+$3.27K	﹤0.01%	535
2016 Q4	–	Sell	-40	Closed	-$2K	–	636
2016 Q3	$2K	Buy	+40	New	+$1.9K	﹤0.01%	535
2015 Q2	–	Sell	-20	Closed	-$2K	–	665
2015 Q1	$2K	Hold	20	–	–	﹤0.01%	520
2014 Q4	$1K	Buy	+20	New	+$1.17K	﹤0.01%	574
2014 Q1	–	Sell	-120	Closed	-$5K	–	625
2013 Q4	$5K	Buy	+120	New	+$4.01K	﹤0.01%	438

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return

TCM

Traynor Capital Management Malvern, Pennsylvania $1.7B AUM 39.15% 1-Year Est. Return

Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Tradewinds Capital Management's BIB Position: Q1 2022 in Review

Tradewinds Capital Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2022, closing a stake of 30 shares — an estimated $2K sold.

Tradewinds Capital Management first reported a position in BIB in Q4 2013 and held it in 8 quarters. The position peaked at $5K in Q4 2013. 28 funds tracked by Wall St. Rank hold BIB as of Q1 2022.

Tradewinds Capital Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q1 2022 after selling out during the quarter.
Tradewinds Capital Management sold 30 ProShares Ultra NASDAQ Biotechnology shares in Q1 2022, an estimated $2K.
Tradewinds Capital Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2013 and held it in 8 quarters.
Tradewinds Capital Management's ProShares Ultra NASDAQ Biotechnology position peaked at $5K in Q4 2013.
28 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2022.

Based on Tradewinds Capital Management's 13F filing for Q1 2022, filed 25 Apr 2022.